Company page

Immunitybio, Inc.

Immunitybio, Inc. is a public company traded under the ticker IBRX in the American market. The company has a market capitalization of approximately $7.44 billion. Immunitybio focuses on developing innovative immunotherapy treatments to enhance the body's immune response against diseases.